Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026)

Prelude Therapeutics (PRLD) reported EBIT Margin of 309.54% for Q1 2026, down 0.63% sequentially from 307.59% in Q4 2025.

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics (PRLD) has 3 years of EBIT Margin data on file, last reported at 309.54% in Q1 2026.

For the quarter ending Q1 2026, EBIT Margin changed N/A year-over-year to 309.54%; the trailing twelve-month figure through Mar 2026 stood at 503.21% (changed N/A YoY), and the FY2025 full-year result was 861.33%, up 113458.0% from the prior year.
EBIT Margin eased to 309.54% in Q1 2026, from 307.59% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 307.59% in Q4 2025 to a low of 1145.87% in Q3 2024.
A 3-year average of 584.58% and a median of 314.12% in 2025 frame the typical range for EBIT Margin.
Peak annual rise in EBIT Margin reached 83174 bps in 2025, while the deepest fall reached 53819 bps in 2025.
Tracing PRLD's EBIT Margin over 3 years: stood at 845.78% in 2024, then soared by 64 bps to 307.59% in 2025, then retreated by 1 bps to 309.54% in 2026.
Business Quant data shows PRLD's EBIT Margin at 309.54% in Q1 2026, 307.59% in Q4 2025, and 314.12% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Prelude Therapeutics	324.30 Mn	179.71 Mn	-	-309.54%

Download Data